150 related articles for article (PubMed ID: 37977106)
1. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
[TBL] [Abstract][Full Text] [Related]
2. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
[TBL] [Abstract][Full Text] [Related]
4. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
[TBL] [Abstract][Full Text] [Related]
5. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
6. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
[TBL] [Abstract][Full Text] [Related]
7. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma.
Mangone A; Altieri B; Detomas M; Prete A; Abbas H; Asia M; Elhassan YS; Mantovani G; Ronchi CL
Endocr Relat Cancer; 2023 Apr; 30(4):. PubMed ID: 36715606
[TBL] [Abstract][Full Text] [Related]
9. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
Sasaki S
Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
[TBL] [Abstract][Full Text] [Related]
10. Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.
Turla A; Laganà M; Grisanti S; Abate A; Ferrari VD; Cremaschi V; Sigala S; Consoli F; Cosentini D; Berruti A
Endocrine; 2022 Sep; 77(3):438-443. PubMed ID: 35567656
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
13. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
Roca E; Berruti A; Sbiera S; Rapa I; Oneda E; Sperone P; Ronchi CL; Ferrari L; Grisanti S; Germano A; Zaggia B; Scagliotti GV; Fassnacht M; Volante M; Terzolo M; Papotti M
Endocr Relat Cancer; 2017 Jul; 24(7):319-327. PubMed ID: 28432084
[TBL] [Abstract][Full Text] [Related]
17. Adrenocortical carcinoma: current treatment options.
De Filpo G; Mannelli M; Canu L
Curr Opin Oncol; 2021 Jan; 33(1):16-22. PubMed ID: 33186181
[TBL] [Abstract][Full Text] [Related]
18. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Laganà M; Grisanti S; Ambrosini R; Cosentini D; Abate A; Zamparini M; Ferrari VD; Gianoncelli A; Turla A; Canu L; Terzolo M; Tiberio GAM; Sigala S; Berruti A
ESMO Open; 2022 Apr; 7(2):100422. PubMed ID: 35272132
[TBL] [Abstract][Full Text] [Related]
20. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
